Lobbying disclosures · Lobbying report
BIIB: third_quarter 2026 lobbying report
Issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment and Lupus. Issues related to the budget and appropriations process Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to the budget and appropriations process
Follow BIIB- Became public
- Oct 20, 2026, 11:09 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 12, 2026, 1:07 AM EST
Why this is connected
Exact legal-name match: BIOGEN INC. (https://www.sec.gov/Archives/edgar/data/875045/).
Reported lobbying amounts
Income: $50,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/cf50cffd-2b02-4f8f-b5e8-9e514efa016b/","filing_uuid":"cf50cffd-2b02-4f8f-b5e8-9e514efa016b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/cf50cffd-2b02-4f8f-b5e8-9e514efa016b/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Paul A. Brathwaite","dt_posted":"2026-10-20T23:09:03-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1220 L Street, NW","registrant_address_2":"Suite 100-401","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401104703,"url":"https://lda.gov/api/v1/registrants/401104703/","house_registrant_id":null,"name":"FEDERAL STREET STRATEGIES, LLC","description":"Government relations and public policy consulting firm","address_1":"1220 L Street, NW","address_2":"Suite 100-401","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL BRATHWAITE","contact_telephone":"+1 202-274-1099","dt_updated":"2026-07-30T23:17:42.705814-04:00"},"client":{"id":205465,"url":"https://lda.gov/api/v1/clients/205465/","client_id":164,"name":"BIOGEN, INC.","general_description":"Biotechnology Company.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment and Lupus. Issues related to the budget and appropriations process","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147906,"prefix":null,"prefix_display":null,"first_name":"KAADE","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent, U.S. Senator Amy Klobuchar; Staff Assistant, U.S. Representative Betty McCollum","new":true},{"lobbyist":{"id":67337,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"BRATHWAITE","suffix":null,"suffix_display":null},"covered_position":"Executive Director, Congressional Black Caucus; Deputy Assistant Secretary of Labor, ESA, Department of Labor; Chief of Staff, ESA, Department of Labor; and Special Assistant, U.S. Secretary of Labor, Department of Labor.","new":true},{"lobbyist":{"id":142566,"prefix":null,"prefix_display":null,"first_name":"VEN","nickname":null,"middle_name":null,"last_name":"NERALLA","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, U.S. Rep. Andy Levin; Deputy Chief of Staff,U.S. Rep. Pramila Jayapal; Legislative Director, U.S. Rep.Barbara Lee; Legislative Assistant, U.S. Rep. Peter DeFazio;Senior Advisor, USDA; OPP; and MCC.","new":true},{"lobbyist":{"id":147905,"prefix":null,"prefix_display":null,"first_name":"STACEY","nickname":null,"middle_name":null,"last_name":"LEAVANDOSKY","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, U.S. Representative Zoe Lofgren; Senior Advisor, Committee on Science, Space & Technology; Senior Advisor, Committee on House Administration; Executive Director, California Democratic Congressional Delegation.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to the budget and appropriations process","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67337,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"BRATHWAITE","suffix":null,"suffix_display":null},"covered_position":"Executive Director, Congressional Black Caucus; Deputy Assistant Secretary of Labor, ESA, Department of Labor; Chief of Staff, ESA, Department of Labor; and Special Assistant, U.S. Secretary of Labor, Department of Labor.","new":true},{"lobbyist":{"id":142566,"prefix":null,"prefix_display":null,"first_name":"VEN","nickname":null,"middle_name":null,"last_name":"NERALLA","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, U.S. Rep. Andy Levin; Deputy Chief of Staff,U.S. Rep. Pramila Jayapal; Legislative Director, U.S. Rep.Barbara Lee; Legislative Assistant, U.S. Rep. Peter DeFazio;Senior Advisor, USDA; OPP; and MCC.","new":true},{"lobbyist":{"id":147906,"prefix":null,"prefix_display":null,"first_name":"KAADE","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent, U.S. Senator Amy Klobuchar; Staff Assistant, U.S. Representative Betty McCollum","new":true},{"lobbyist":{"id":147905,"prefix":null,"prefix_display":null,"first_name":"STACEY","nickname":null,"middle_name":null,"last_name":"LEAVANDOSKY","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, U.S. Representative Zoe Lofgren; Senior Advisor, Committee on Science, Space & Technology; Senior Advisor, Committee on House Administration; Executive Director, California Democratic Congressional Delegation","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in BIIB
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Oct 7, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
$1K–$15K · Traded Sep 24, 2026 · disclosed Oct 7, 2026
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 11, 2026 · disclosed Oct 7, 2026 · Dependent
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Sep 1, 2026$1K–$15K
Rep. Kevin Hern (R-OK-1)
$1K–$15K · Traded Aug 18, 2026 · disclosed Sep 1, 2026
Got $5K from the company’s PAC - Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jul 7, 2026$15K–$50K
Rep. Maria Elvira Salazar (R-FL-27)
$15K–$50K · Traded Jun 2, 2026 · disclosed Jul 7, 2026
- Jul 2, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Jun 5, 2026 · disclosed Jul 2, 2026
- Jun 8, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
$1K–$15K · Traded May 12, 2026 · disclosed Jun 8, 2026
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.